# DIAbetes Maximal ACCeleration

Study · id `cardio:ct-nct05646147` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05646147](<https://clinicaltrials.gov/study/NCT05646147>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05646147

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 238 participants.

## Technical summary

Registry record NCT05646147. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-07 (anticipated); primary completion 2025-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 238 participants (planned count; ClinicalTrials.gov record NCT05646147, source copy `cardio:ctgov-nct05646147-2023-03-10`, retrieved 2026-10-26)
- Planned start: 2023-07 (anticipated) (ClinicalTrials.gov record NCT05646147, source copy `cardio:ctgov-nct05646147-2023-03-10`, retrieved 2026-10-26)
- Primary completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT05646147, source copy `cardio:ctgov-nct05646147-2023-03-10`, retrieved 2026-10-26)
- Completion: 2025-07 (anticipated) (ClinicalTrials.gov record NCT05646147, source copy `cardio:ctgov-nct05646147-2023-03-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05646147-2023-03-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: DIAbetes Maximal ACCeleration
- Acronym: DIAMACC
- Condition: Peripheral Arterial Disease
- Condition: Diagnosis
- Condition: Diabetic Foot
- Intervention (Device): Maximal Systolic Acceleration
- Lead sponsor: Leiden University Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Leiden University Medical Center (`cardio:org-leiden-university-medical-center`)

## Provenance

Content hash: fd090ea13fbb59b836b43f7000a233d4cbe256ac8c83f14c92b37d4bd8c6f490
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
